About this trial
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.
The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.
Eligibility criteria
Qualifiers
Time between intubation and ECMO cannulation is less than 240 hours (10 days)
ECMO support type is respiratory (VV or VA cannulation)
Chest radiograph with bilateral lung disease
Disqualifiers
Previously enrolled in PROSpect
Perinatal related lung disease
Congenital diaphragmatic hernia or congenital/acquired diaphragm paralysis
Respiratory failure caused by cardiac failure or fluid overload
Trial design
Treatments tested in this trial
- ECMO support
- PROSpect protocolized therapies
Treatment groups
Sponsors and collaborators
University of Michigan
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator